NEWARK, NJ, United States, via eTeligis Inc., 06/05/2014 - - BioNeutral Group, Inc. (OTC Pink: BONU) (PINKSHEETS:BONU),
I would like to take a moment to thank you for your continued support in the past and brief you on some of the new important developments with the company. In the past as you know we've communicated with stockholders primarily through our filings and periodic press releases. Now that the commercialization stage of the company's development has begun to unfold we will endeavor to do it not only more frequently but directly.
Over the last year, the company has developed and continually modified a comprehensive business plan to include all aspects of the business, finance, operations, sales, marketing and R&D, the focus of which is to commercially leverage our technology. During that time, we completed our independent testing of our YGIENE™ sterilant, recruited key sales executives, important consultants and independent members of our board of directors. We also brought two law suits one seeking to regain the lost distribution rights in Asia and Europe and the other to recover damages from what proved to be fraudulently granted contracts. Both these suits proved to be successful.
Beginning in 2013, we began to commercialize our YGIENE™ technology. Most importantly, we learned that there was a significant need for YGIENE™ and that the product performed as promised under actual marketplace conditions. Building on this strength over the last five months we've established relationships with three key distributors. Each one specializes in at least one of three key markets of interest, lab research, Long Term Care and mold remediation among others. As a result, we now as of this month are represented by approximately 115 sales representatives in various parts of the country who will not only be presenting our products to their customers but exhibiting them at key industry trade events. In addition, we have several Private Label discussions under way with various manufacturers both in the U.S. and overseas as well as continuing conversations with additional U.S. distributors. These discussions, if proven fruitful would position the company in important additional market segments as well.
Based on the initial highly favorable impression YGIENE™ has made on the trade we introduced in 2014 a line extension program aimed at broadening our product line to include a YGIENE™ Cleaner and an OGIENE™ Air freshener both to be available in several versions. These new products offer unsurpassed end benefits commiserate with the basic YGIENE™ selling proposition and as such each complements the other. We have also in the first half of this year begun initial development of new exciting applications of our basic technology, which while somewhat longer term in nature, will broaden the current product line even further.
In addition, we have entered into a distribution agreement to market a consumer version of our OGIENE™ air freshener in the U.K with eventual expansion to the balance of Europe. As a result of this activity, we believe that the business will soon begin to have "traction" (certainly the enthusiasm of our Distributors, each of whom are, and for a long time have been, market participants, seem to think so) and we anticipate that we will soon be operating at a meaningful level of sales.
As you are undoubtedly aware during this time our stock price has declined significantly. This is due, we believe, to the fact that we've been forced to significantly increase our share base in order to fund our working capital needs. As we continue to expand our commercialization process, bringing news to the marketplace in the process hopefully our share price will increase.
Lastly, we are pleased to have recently engaged the STAT Group to assist us in communicating our current developments and answering investor and media inquiries. S.T.A.T. representatives have been helping small capitalized companies for over a decade communicate with the investing community.
Sincerely,
/s/Mark Lowenthal, President & CEO
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™ kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to YGIENE-206. BioNeutral's antimicrobial formulations will be marketed under the brand name YGIENE™ and are available for sale in the United States.
CONTACTS:
FOR THE COMPANY:
Mark Lowenthal
CEO
BioNeutral Group, Inc.
+1-973-577-8003
Craig Fisher
S.T.A.T Group LLC
+1-786-375-0556
SOURCE: BioNeutral Group, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
BONU_6-5-2014_ALD_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment